Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

JAZZ Relative to the S&P 500

JAZZ Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Jazz Pharmaceuticals, Inc. (NASD:JAZZ) seasonal charts above shows that a Buy Date of November 7 and a Sell Date of January 27 has resulted in a geometric average return of 6.25% above the benchmark rate of the S&P 500 Total Return Index over the past 15 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a very good rate of success, but the return underperforms the relative buy-and-hold performance of the stock over the past 15 years by an average of 1.56% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

To download JAZZ seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: JAZZ